Post-approval, Observational study to assess safety and effectiveness of Sitagliptin+Glimepiride+Metformin in patients with diabetes on dual therapy in real-lifesettings of India. - (GLIMSI study)

Torrent Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月1日

试验速览

暂无简介。

•Male or Female patients 18 to 65 years. Patients uncontrolled on dual therapy (Glimepiride + Metformin) or (Sitagliptin + Metformin) with HbA1c more than 7.5 & less than 8.5 %. Treatment-naïve with HbA1c more than 7.0 & less than 9.0%. Patients with FBG more than 126 mg/dl & PPG more than 200 mg/dl. Patients not taking any other OAD drugs. Patient willing to enroll for the study.

•History of Type 1 diabetes.
•Patients were treated with insulin within 8 weeks of screening.
•Patients with renal dysfunction (crcl less than 60 ml/min) or proteinuria.
•History of hypersensitivity.
•Intolerance to the use of Sitagliptin, Glimepiride or Metformin.
•Pregnant and lactating women.
•Patients with Congestive Heart Failure, Unstable angina or ACS within past 6 months.

发起方

Torrent Pharmaceuticals Ltd